This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
by Zacks Equity Research
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.
Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.
DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged
by Zacks Equity Research
Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.
Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.
LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The robust year-over-year revenue growth across Thermo Fisher's (TMO) Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.
West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.
Align Technology (ALGN) Q1 Earnings Lag Estimates, Margins Fall
by Zacks Equity Research
Robust Clear Aligner case volume growth and increased uptake of the iTero Element 5D Plus are driving Align Technology's (ALGN) first-quarter top line.
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.
Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q4 top line.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Healthcare ETFs in Focus Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
Centene (CNC) Q1 Earnings Beat Estimates, Ups '22 EPS View
by Zacks Equity Research
Centene's (CNC) first-quarter results highlight improved premium and service revenues and, higher membership growth. An increased 2022 guidance with respect to EPS and revenues should impress investors.
Has Molina Healthcare (MOH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Molina (MOH) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
Stock Market News for Apr 25, 2022
by Zacks Equity Research
U.S. stocks ended sharply lower on Friday, recording their worst day since 2020, as a fresh batch of corporate earnings and sharp near-term rate hike prospects led to massive selloffs.
HCA Healthcare (HCA) Q1 Earnings Miss, Trims '22 EPS View
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results reflect elevated expenses related to salaries and benefits, partly offset by an uptick in revenues driven by higher patient admissions.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Anthem (ANTM) Q1 Earnings Beat Estimates, Hikes '22 EPS View
by Zacks Equity Research
Anthem's (ANTM) first-quarter results indicate solid top-line growth and strong contribution from each of its businesses, partly offset by higher expenses.